These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9676726)

  • 1. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
    Cohen DS; Mathis JE; Dotson RA; Graybill SR; Wosu NJ
    J Cardiovasc Pharmacol; 1998 Jul; 32(1):87-95. PubMed ID: 9676726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
    Webb RL; Abramson ML; Beil ME; Odorico LM; Chatelain RE
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):632-42. PubMed ID: 9388046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.
    Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G
    Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin II.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Mathers PD; Rogers WL; Dorso CR
    J Cardiovasc Pharmacol; 1996 Nov; 28(5):651-8. PubMed ID: 8945678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat.
    Golin R; Protasoni G; Wjinmaalen P; Sala C; Monopoli A; Casati C; Zanchetti A; Stella A
    J Cardiovasc Pharmacol; 1996 Nov; 28(5):665-71. PubMed ID: 8945680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protective effects of blocking the intrarenal renin-angiotensin system.
    Li J; Zhou C; Yu L; Wang H
    Hypertens Res; 1999 Sep; 22(3):223-8. PubMed ID: 10515446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
    Ying L; Flamant M; Vandermeersch S; Boffa JJ; Chatziantoniou C; Dussaule JC; Chansel D
    Hypertension; 2003 Nov; 42(5):937-44. PubMed ID: 14569001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
    Kuro T; Okahara A; Nose M; Ikuse T; Matsumura Y
    Biol Pharm Bull; 2000 Jul; 23(7):820-5. PubMed ID: 10919359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
    Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
    Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.